Exit

CrowdStrike considers 2019 IPO
The endpoint security software producer has hired Goldman Sachs for an initial public offering that would enable Alphabet, Rackspace and Telstra to exit.
Revolution acquires Warp Drive to accelerate progress
Warp Drive Bio, the genomic medicine developer co-founded by Sanofi, has agreed to an all-share acquisition by Revolution Medicines.
Palantir puts 2019 IPO on the plate
The Relx-backed data miner could double its valuation to $41bn in the proposed offering, according to prospective underwriters.
SI-Bone burrows into public markets with $108m IPO
The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.
Equillium enters public markets
Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.
Uber and Lyft take another step toward public markets
Banks have reportedly suggested a $120bn valuation for Uber's IPO, while Lyft has chosen JP Morgan to lead an offering that could value it at more than $15bn.
Allogene closes IPO at nearly $373m
The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.
Turnitin marks Gradescope for acquisition
Gradescope has paid an undisclosed amount to acquire schoolwork analysis software developer Turnitin, which had raised more than $5m from investors including Bloomberg.

Other News

Alibaba merges Ele.me with Koubei
Alibaba will merge its online food delivery subsidiary Ele.me with its local services spinoff Koubei, following earlier reports that SoftBank was joining Alibaba to invest about $3bn of funding in the new business.
Anaplan raises $264m in IPO
Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.
Allogene rallies to $324m IPO
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
Dealflow maintains pace in September
This is our data snapshot based on last month’s investment activity. 
The charts and tables have been generated by our data platform GCV Analytics.
Strong third quarter for corporate venturing
The following is a snapshot of the data we have collected on investment activity over the past three months. To verify reported deals, we contact about 300 corporate investors each quarter – these comprise roughly 18% of the global CVCs we cover, but account for most of the deals that are made public.
Twist Bio turns to IPO filing
The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.

Editor's Picks

Palantir puts 2019 IPO on the plate
The Relx-backed data miner could double its valuation to $41bn in the proposed offering, according to prospective underwriters.
Allogene rallies to $324m IPO
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
Orchard to orchestrate $173m IPO
GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
Redlock heads to Palo Alto in $173m acquisition
Dell Technologies Capital will exit Redlock in an acquisition by Palo Alto Networks, five months after it bought another cloud security software developer.
test reg

Login

Not yet subscribed?

See your subscription offers here